Microglial Toll-like Receptor-4 and Ischemic Preconditioning
小胶质细胞 Toll 样受体 4 和缺血预处理
基本信息
- 批准号:8133334
- 负责人:
- 金额:$ 14.92万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-09-01 至 2014-08-31
- 项目状态:已结题
- 来源:
- 关键词:Adverse effectsAgonistAntibodiesAreaBiochemicalBiological AssayBrainBrain InjuriesCause of DeathCellsCerebral IschemiaChaperonin 60EnzymesExperimental ModelsExposure toFlow CytometryFunctional disorderGene ExpressionGene Expression ProfileGoalsHeat shock proteinsHypoglycemiaHypoxiaHypoxia Inducible FactorImmuneImmune responseIn VitroInfarctionInflammatoryInflammatory InfiltrateInflammatory ResponseInjuryInterventionInvestigationIschemiaIschemic Brain InjuryIschemic PenumbraIschemic PreconditioningKnock-outKnowledgeLipopolysaccharidesMediatingMediator of activation proteinMicrogliaMiddle Cerebral Artery OcclusionModelingMolecularMolecular TargetMouse StrainsMusMyeloid CellsNuclear TranslocationOutcomeOxygen measurement, partial pressure, arterialPatternPattern recognition receptorPeripheralPhenotypeProcessProteinsRegulator GenesRelative (related person)Reperfusion TherapyResearchResearch PersonnelResearch Project GrantsResistanceRoleSignal TransductionSorting - Cell MovementSourceStimulusStrokeSurface AntigensTestingTherapeutic InterventionTissuesToll-like receptorsUnited StatesValidationWorkacute strokeattenuationcellular targetingchemokinecytokinedisabilityhypoxia inducible factor 1in vivoin vivo Modelinsightmacrophagemicrobialmouse toll-like receptor 4neurobehavioralneuroinflammationneuroprotectionnovelpathogenpreconditioningpublic health relevanceresearch studyresponsetoll-like receptor 4
项目摘要
DESCRIPTION (provided by applicant):
This proposal focuses on characterizing the role of microglial toll-like receptor-4 (TLR4) in ischemic preconditioning (IPC). IPC is a robust neuroprotective phenomenon in which a brief period of cerebral ischemia confers transient tolerance to subsequent ischemic challenge. Characterization of the cellular and molecular mechanisms that underlie IPC is an important and active area of investigation in stroke research. Inflammatory responses in the brain are critical in the pathophysiology of stroke. Microglia, the brain's resident tissue macrophages, are central in this process. TLRs mediate powerful immune responses to a variety of pathogen associated molecular patterns including lipopolysaccharide (LPS). TLR4, which is expressed by microglia in the CNS, has been directly implicated in the pathophysiology of stroke. However, the role of microglial TLR4 signaling in IPC is unknown. Here we hypothesize that microglial TLR4 signaling is required for both optimal IPC-mediated neuroprotection and IPC-mediated attenuation of inflammatory responses seen in subsequent prolonged ischemia (stroke). We further postulate that hypoxia-inducible factor-11 (HIF-11), a central regulator of gene expression under low oxygen tension, is critical in mediating the effects of microglial TLR4 signaling on IPC. To test these hypotheses, we will first use a well-established in vivo model of stroke/IPC (mouse middle cerebral artery occlusion/reperfusion paradigm) on TLR4 knockout and control mice. We will assess infarct volume and neurobehavioral outcome. Then we will use ex vivo flow cytometry to characterize the inflammatory infiltrate and microglial phenotype in ischemic cortex following stroke alone, IPC alone or IPC followed by stroke. Second, we will carry out in vitro ischemia experiments on cultured primary microglia from TLR4 knockout and control mice to characterize the role of TLR4 signaling in modulating the microglial response to hypoxia/hypoglycemia. Third, we will use a myeloid-cell targeted, HIF-11 knockdown mouse strain, in addition to the systemic TLR4 knockout strain, to investigate in vivo the role of HIF-11 in mediating the effects of microglial TLR4 signaling on IPC. The results of these studies will be valuable to researchers trying to elucidate the cellular and molecular mechanisms of IPC, neuroinflammation and stroke. It will provide key insights into the pathophysiologic state of microglia in the ischemic penumbra and identify molecular targets for therapeutic intervention in acute stroke.
PUBLIC HEALTH RELEVANCE:
Stroke is the leading cause of serious long-term disability and the third leading cause of death in the United States. Currently available pharmacologic therapies for acute stroke are few in number and limited by temporal restrictions on their use, modest efficacy and potential for serious side effects. A major goal of this research project is to increase our mechanistic understanding of stroke pathophysiology. By doing so, we hope to identify novel cellular and molecular targets for therapeutic intervention in acute stroke.
描述(由申请人提供):
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JONATHAN R WEINSTEIN其他文献
JONATHAN R WEINSTEIN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JONATHAN R WEINSTEIN', 18)}}的其他基金
Role of Microglia in Cerebral Small Vessel Disease (CSVD)/Vascular Cognitive Impairment (VCI)
小胶质细胞在脑小血管病 (CSVD)/血管认知障碍 (VCI) 中的作用
- 批准号:
10662565 - 财政年份:2022
- 资助金额:
$ 14.92万 - 项目类别:
Repurposing of KCa3.1 Inhibitor Senicapoc for Stroke: A Pre-clinical Study
KCa3.1 抑制剂 Senicapoc 治疗中风的再利用:临床前研究
- 批准号:
10290659 - 财政年份:2021
- 资助金额:
$ 14.92万 - 项目类别:
Repurposing of KCa3.1 Inhibitor Senicapoc for Stroke: A Pre-clinical Study
KCa3.1 抑制剂 Senicapoc 治疗中风的再利用:临床前研究
- 批准号:
10463846 - 财政年份:2021
- 资助金额:
$ 14.92万 - 项目类别:
Single cell RNA-seq characterization of CNS myeloid cells after ischemic preconditioning
缺血预处理后 CNS 骨髓细胞的单细胞 RNA-seq 表征
- 批准号:
10041730 - 财政年份:2020
- 资助金额:
$ 14.92万 - 项目类别:
Microglial Interferon Signaling and Ischemic Preconditioning
小胶质细胞干扰素信号转导和缺血预处理
- 批准号:
8220546 - 财政年份:2011
- 资助金额:
$ 14.92万 - 项目类别:
Microglial Interferon Signaling and Ischemic Preconditioning
小胶质细胞干扰素信号转导和缺血预处理
- 批准号:
8516609 - 财政年份:2011
- 资助金额:
$ 14.92万 - 项目类别:
Microglial Interferon Signaling and Ischemic Preconditioning
小胶质细胞干扰素信号转导和缺血预处理
- 批准号:
8332299 - 财政年份:2011
- 资助金额:
$ 14.92万 - 项目类别:
Microglial Interferon Signaling and Ischemic Preconditioning
小胶质细胞干扰素信号转导和缺血预处理
- 批准号:
8712571 - 财政年份:2011
- 资助金额:
$ 14.92万 - 项目类别:
Microglial Toll-like Receptor-4 and Ischemic Preconditioning
小胶质细胞 Toll 样受体 4 和缺血预处理
- 批准号:
7787154 - 财政年份:2009
- 资助金额:
$ 14.92万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 14.92万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 14.92万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 14.92万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 14.92万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 14.92万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 14.92万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 14.92万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 14.92万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 14.92万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 14.92万 - 项目类别:
Grant-in-Aid for Scientific Research (C)














{{item.name}}会员




